AI-Powered Drug Repurposing: A Paradigm Shift for Treating Rare Diseases

Rasit Dinc

Rasit Dinc Digital Health & AI Research

Published: September 16, 2025 | AI Diagnostics

DOI: 10.5281/zenodo.17996551

Abstract

Meta Description: Explore how Artificial Intelligence AI is revolutionizing drug repurposing for rare diseases, overcoming challenges like data scarcity and ...

Meta Description: Explore how Artificial Intelligence (AI) is revolutionizing drug repurposing for rare diseases, overcoming challenges like data scarcity and accelerating the delivery of life-saving treatments.

The Unmet Need in Orphan Drug Development

The landscape of rare diseases (RDs) presents a profound challenge in modern medicine. With over 7,000 identified RDs affecting millions globally, less than 6% currently have an approved treatment option [1]. The traditional drug development pipeline—a process that is costly and time-consuming—is ill-suited for RDs, which are characterized by small patient populations, complex biology, and a scarcity of high-quality clinical data. This significantly increases the risk and cost of developing novel therapies.

In this context, **drug repurposing** (DR), the strategy of identifying new therapeutic uses for existing, approved drugs, has emerged as a critical, innovative pathway. DR offers substantial advantages, including reduced development time, lower costs, and a higher probability of success, as the safety and pharmacokinetic profiles of the compounds are already established [1]. However, even with these benefits, the sheer volume of existing compounds and the complexity of matching them to the subtle, varied pathologies of RDs still require a powerful, systematic approach.

Artificial Intelligence: The Accelerator for Drug Repurposing

The convergence of DR with **Artificial Intelligence (AI)**, particularly machine learning (ML) and deep learning (DL), is now creating a paradigm shift in the treatment of RDs. AI's core strength lies in its ability to integrate and analyze vast, heterogeneous datasets—a capability essential for overcoming the data scarcity inherent to RDs [1].

AI algorithms can process and synthesize information from diverse sources, including genomic and proteomic data to identify disease-related molecular targets and pathways, Electronic Health Records (EHRs) to uncover subtle drug-disease associations from real-world patient data, biomedical literature and clinical trials to extract and structure siloed knowledge, and chemical and biological databases to predict drug-target interactions and off-target effects.

By leveraging these data streams, AI models can rapidly screen thousands of existing compounds against a disease's molecular signature, dramatically accelerating the identification of promising drug candidates.

Cutting-Edge AI Methodologies

The sophistication of AI models is continually advancing, moving beyond simple pattern recognition to complex, predictive modeling. A notable recent development is the introduction of **graph foundation models**, such as TxGNN, which are designed for **zero-shot drug repurposing** [3]. These models use graph neural networks to represent the complex relationships between drugs, targets, diseases, and genes. By learning from the entire biomedical knowledge graph, they can predict therapeutic candidates for diseases with virtually no prior treatment associations—a common scenario in the RD space.

The efficacy of these advanced models is proving transformative. For instance, a new AI tool developed for DR was recently reported to be nearly 50% better, on average, than leading AI models at identifying viable drug candidates, underscoring the rapid progress and competitive advantage new computational methods are bringing to the field [2]. These tools are not just faster; they are more accurate and capable of uncovering non-obvious connections that human researchers might miss.

Real-World Impact and Investment

The theoretical promise of AI-DR is rapidly translating into real-world initiatives and significant investment. Governments and private organizations are recognizing the potential to address the "orphan drug" crisis. For example, the Advanced Research Projects Agency for Health (ARPA-H) has awarded funding to AI-driven projects specifically aimed at repurposing approved medications to find treatments for the millions of Americans affected by RDs [4].

This investment is crucial, as it supports the development of robust platforms and the validation of AI-generated hypotheses through *in vitro* and *in vivo* studies. The ultimate goal is to create a streamlined, data-driven pipeline that can reduce the time from hypothesis generation to clinical trial initiation from years to months.

Challenges and the Path Forward

Despite the immense potential, the AI-DR field for RDs faces several critical challenges that must be addressed to ensure its sustained success:

Challenge	Description
Data Quality and Scarcity	The

limited and heterogeneous nature of RD data (e.g., small patient cohorts, varied diagnostic criteria) can bias or limit the training of robust AI models. | | **Model Interpretability** | "Black box" models can make it difficult for clinicians and regulators to trust and validate the AI's predictions, hindering clinical adoption. | | **Regulatory Pathway** | Clear, accelerated regulatory guidelines are needed for AI-generated DR candidates to ensure a smooth transition from computational prediction to patient access. | | **Validation and Clinical Trials** | Computational predictions must be rigorously validated in the lab and through clinical trials, which remain challenging due to the rarity of patient populations. |

The path forward requires a collaborative ecosystem involving AI developers, pharmaceutical companies, patient advocacy groups, and regulatory bodies. By focusing on creating standardized, high-quality data repositories and developing transparent, explainable AI models, the digital health community can fully harness the power of AI to deliver on the promise of effective, accessible treatments for rare diseases. This synergy between AI and drug repurposing is a vital, life-changing engine for therapeutic innovation.

**

References

[1] Cortial, L., Montero, V., Tourlet, S., Del Bano, J., & Blin, O. (2024). Artificial intelligence in drug repurposing for rare diseases: a mini-review. Frontiers in Medicine*, 11, 1404338. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11150798/] (https://pmc.ncbi.nlm.nih.gov/articles/PMC11150798/)*

[2] Using AI to repurpose existing drugs for treatment of rare diseases. (2024, September 25). Harvard Gazette*. [https://news.harvard.edu/gazette/story/2024/09/using-ai-to-repurpose-existing-drugs-for-treatment-of-rare-diseases/] (https://news.harvard.edu/gazette/story/2024/09/using-ai-to-repurpose-existing-drugs-for-treatment-of-rare-diseases/)*

[3] Huang, K., et al. (2024). A foundation model for clinician-centered drug repurposing. Nature Medicine*. https://www.nature.com/articles/s41591-024-03233-x*

[4] ARPA-H awards AI-driven project to repurpose approved medications. (2024, February 28). ARPA-H News and Events*. [https://arpa-h.gov/news-and-events/arpa-h-awards-ai-driven-project-repurpose-approved-medications] (https://arpa-h.gov/news-and-events/arpa-h-awards-ai-driven-project-repurpose-approved-medications)